News

Public · Published

Moderna (MRNA) Raises 2026 Revenue Growth Outlook to 15%–25%

Moderna raised its 2026 revenue growth outlook to 15%–25%, from its original outlook of up to 10%. It also expects about 10 percentage points of gross margin expansion, excluding a litigation settlement charge, approximately $4B in 2027 cash costs, and approximately $9B in total liquidity at year-end 2026.

Published:

Updated:

What happened

Moderna raised its 2026 revenue growth outlook to 15%–25%, from its original outlook of up to 10%. It also expects about 10 percentage points of gross margin expansion, excluding a litigation settlement charge, approximately $4B in 2027 cash costs, and approximately $9B in total liquidity at year-end 2026.

Confirmed

Global impact / market context

The higher growth outlook suggests Moderna expects more revenue, while the projected gross margin expansion could mean more revenue remains after production costs. But approximately $4B of expected 2027 cash costs could absorb funds, so the balance between growth, spending and cash available matters to investors.

Analyst inference

This update pairs a stronger 2026 sales outlook with substantial cash costs expected in 2027 and an estimate of total liquidity, meaning cash, investments and borrowing capacity not yet used. Together, these figures shape expectations for revenue growth and funding needs, not just cash on hand.

Analyst inference

What to watch

  1. Check whether reported 2026 revenue growth reaches the 15%–25% outlook and whether gross margin expands by about 10 percentage points, excluding the settlement charge. Analyst inference
  2. Compare actual 2027 cash costs with the approximately $4B expectation, especially as the article identifies oncology investment as a primary driver of those costs. Analyst inference
  3. Moderna expects to provide formal 2027 guidance on its Q4 2026 earnings call; that update could clarify its spending and growth plans. Confirmed

Evidence

  • Original source link unavailable